Literature DB >> 16421948

CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA.

Kei Yasuda1, Mark Rutz, Beatrix Schlatter, Jochen Metzger, Peter B Luppa, Frank Schmitz, Tobias Haas, Antje Heit, Stefan Bauer, Hermann Wagner.   

Abstract

Endosomally translocated host (self) DNA activates Toll-like receptor 9 (TLR9), while extracellular self-DNA does not. This inconsistency reflects poor endosomal DNA translocation but also implies that host DNA contains DNA sequences that function as ligands for TLR9. Herein we report that contrary to phosphorothioate (PS)-stabilized oligonucleotides (ODN), "natural" phosphodiester (PD) ODN lacking CpG motifs activate TLR9. CpG motif-independent TLR9 activation of Flt3-L-induced dendritic cells (DC) was dependent on enforced endosomal translocation and triggered upregulation of CD40 and CD69 as well as production of IL-6 and IFN-alpha. Binding studies utilizing surface plasmon resonance technology (Biacore) revealed low TLR9 binding to single-stranded (ss) PD-ODN lacking CpG motifs. At higher concentrations their TLR9 binding activity compared well with TLR9 binding of canonical ss PD CpG-ODN. These results imply that both the chemical modification of the DNA backbone as well as the amount of endosomally translocated DNA represent determining factors that allow CpG motif-independent activation of TLR9 by ss PD-DNA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421948     DOI: 10.1002/eji.200535210

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  34 in total

1.  Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of Toll-like receptor-9 activation in plasmacytoid dendritic cells.

Authors:  Tobias Haas; Frank Schmitz; Antje Heit; Hermann Wagner
Journal:  Immunology       Date:  2008-11-15       Impact factor: 7.397

2.  FcγRIIIa Signaling Modulates Endosomal TLR Responses in Human CD4+ T Cells.

Authors:  Anil K Chauhan
Journal:  J Immunol       Date:  2017-05-12       Impact factor: 5.422

3.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

Review 4.  TLR7 and TLR9 in SLE: when sensing self goes wrong.

Authors:  T Celhar; R Magalhães; A-M Fairhurst
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

5.  DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells.

Authors:  Takaharu Yoshinaga; Kei Yasuda; Yoshiyuki Ogawa; Makiya Nishikawa; Yoshinobu Takakura
Journal:  Immunology       Date:  2006-12-20       Impact factor: 7.397

Review 6.  Trafficking of endosomal Toll-like receptors.

Authors:  Bettina L Lee; Gregory M Barton
Journal:  Trends Cell Biol       Date:  2014-01-15       Impact factor: 20.808

7.  Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury.

Authors:  Zubin M Bamboat; Vinod P Balachandran; Lee M Ocuin; Hebroon Obaid; George Plitas; Ronald P DeMatteo
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

8.  Toll-like receptors in hepatic ischemia/reperfusion and transplantation.

Authors:  John Evankovich; Timothy Billiar; Allan Tsung
Journal:  Gastroenterol Res Pract       Date:  2010-08-05       Impact factor: 2.260

Review 9.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 10.  Injection site reactions after subcutaneous oligonucleotide therapy.

Authors:  Leonie van Meer; Matthijs Moerland; Jolie Gallagher; Martijn B A van Doorn; Errol P Prens; Adam F Cohen; Robert Rissmann; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.